Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/jbg3me73

ANALYSIS OF PERITONEAL FLUID CYTOLOGY: CORRELATIONS WITH CLINICAL AND BIOCHEMICAL FINDINGS

Sonali Bandil[1], Anish Kumar[2], Garima Singh[3], Shubhangee Arya[4*], Naushad Hussian[5]

[1]Associate Professor, Department of Pathology, ASMC, Firozabad, UP
[2]Associate Professor, Department of Orthopedics, ASMC, Firozabad, UP
[3]Associate professor, Department of Blood Bank, ASMC, Firozabad, UP
[4*]Assistant Professor, Department of Pathology, ASMC, Firozabad, UP
[5]Professor and Head, Department of Pathology, ASMC, Firozabad, UP

***Corresponding Author:** Shubhangee Arya
*Assistant Professor, Department of Pathology, Autonomous State Medical College, Firozabad, UP,
Email: aryashubh27@gmail.com

Abstract

Introduction: The analysis of peritoneal fluid, obtained through paracentesis, provides valuable insights into the pathological processes occurring within the peritoneal cavity. The correlation between cytological findings and clinical as well as biochemical parameters is crucial for accurate diagnosis and management of abdominal diseases. Studies have shown that the cytological analysis of peritoneal fluid can offer significant prognostic and diagnostic information, particularly in cases of abdominal cancers such as ovarian and gastric cancer.

Materials & Methods: This prospective study was conducted at a teaching hospital in Firozabad over a period of one and a half years, from Feb. 2022 to August 2024. A total of 60 cases involving ascitic fluids using purposive sampling were included in the study. Ascitic fluid was obtained through paracentesis and collected in sterile containers for analysis. Fluid samples were subjected to routine analysis including total white blood cell (WBC) and red blood cell (RBC) counts using Neubauer's chamber, Sediment from the fluid was prepared and examined microscopically**.**

Results: Majority of the cases were males (76.6%) while females were (23.4%). majority of the cases were in the age group of 41-50 years followed by 1-40 years Liver cirrhosis was found to be the most common cause of Ascitic fluid (51.6%) followed by Anemia- Hypoproteinemia (15%) followed by Nephrotic Syndrome (10%). The colour of ascetic fluid was yellow in majority of liver cirrhosis patients while it was Turbid in all malignant patients and Spontaneous Bacterial Peritonitis patients. In patients of Anemia- Hypoproteinemia, the colour was yellow in majority of patients. The ascitic fluid was transudate in nature in in majority of liver cirrhosis patients while it was exudate in all patients of Malignancy and Spontaneous Bacterial Peritonitis patients.

Conclusion: The effectiveness of this approach is contingent upon standardization of techniques, comprehensive integration with clinical and biochemical data, and addressing variability and potential biases. While the findings offer promising implications for improved patient management and targeted treatment strategies, ongoing research and refinement are essential to fully realize the benefits and address the limitations observed in this study.

Keywords: Peritoneal Fluid Cytology, Clinical, Biochemical

INTRODUCTION

Peritoneal fluid cytology is a critical diagnostic tool used in the assessment of various abdominal conditions, particularly malignancies and infections. The analysis of peritoneal fluid, obtained through paracentesis, provides valuable insights into the pathological processes occurring within the peritoneal cavity. The correlation between cytological findings and clinical as well as biochemical parameters is crucial for accurate diagnosis and management of abdominal diseases.

In recent years, there has been a growing body of research exploring the relationship between peritoneal fluid cytology and clinical outcomes. Studies have shown that the cytological analysis of peritoneal fluid can offer significant prognostic and diagnostic information, particularly in cases of abdominal cancers such as ovarian and gastric cancer. [1, 2] Indian researchers have contributed extensively to this field, highlighting the unique patterns observed in the Indian population and the relevance of cytological findings in the context of local epidemiological trends.

Agarwal and colleagues [3] in their study demonstrated that peritoneal fluid cytology is a valuable adjunct in the diagnosis of ovarian cancer, with specific cytological features correlating with tumor type and stage. Similarly, Bansal et al. [4] provided evidence on how peritoneal fluid cytology can aid in distinguishing between benign and malignant conditions in the Indian context, emphasizing the importance of integrating cytological findings with clinical and biochemical data for a comprehensive diagnostic approach.

On the international front, research by Levine and Barkan[5] highlighted the utility of peritoneal fluid cytology in detecting early-stage ovarian cancer and its prognostic significance. Their findings support the notion that peritoneal fluid analysis can be a predictive tool for patient outcomes, particularly when combined with clinical and biochemical parameters. Additionally, a study by Jones et al.[6] illustrated how variations in peritoneal fluid cytology can reflect underlying systemic conditions, thus aiding in the differential diagnosis of abdominal pathologies.

The interplay between cytological findings and other diagnostic modalities underscores the need for a multidisciplinary approach to patient management. In this context, the integration of peritoneal fluid cytology with clinical assessments and biochemical markers offers a more nuanced understanding of abdominal diseases.[7] As research continues to evolve, both Indian and international studies contribute to refining the diagnostic and prognostic capabilities of peritoneal fluid analysis.

The present study aims to detect malignancy in ascitic fluids along with its differentiation into transudates and exudates and to correlate its characteristics with clinical findings. The objectives of the study were:

1. **Detection of Malignancy:** To perform cytological analysis of ascitic fluids to detect and confirm the presence of malignant cells and to evaluate the sensitivity and specificity of peritoneal fluid cytology in diagnosing malignancy.
2. **Fluid Classification:** To measure fluid protein levels in ascitic fluids and apply established criteria to differentiate between transudates and exudates and to compare fluid protein parameters with clinical diagnoses and outcomes to validate the classification method.
3. **Correlation with Clinical Findings:** To correlate the presence of malignant cells and the classification of ascitic fluids (transudate vs. exudate) with clinical findings such as patient symptoms, disease history, and physical examination results and to assess how the classification of ascitic fluids impacts the diagnostic and management strategies for patients with ascites.
4. **Prognostic and Diagnostic Implications:** To explore the prognostic significance of cytological findings and fluid classification in relation to patient outcomes, including response to treatment and disease progression and to determine if specific patterns in fluid protein levels and cytological results can predict clinical outcomes or influence treatment decisions.

MATERIAL & METHODS

This prospective study was conducted at a teaching hospital in Firozabad over a period of one and a half years, from Feb. 2022 to August 2024. A total of 60 cases involving ascitic fluids using purposive sampling were included in the study.

The study included patients above 18 years of age of either sex presenting with ascites diagnosed and confirmed by physicians, Patients with nephrotic syndrome, Patients with severe anemia and hypoproteinemia and Patients with spontaneous bacterial peritonitis were included in the study after taking written informed consent. However critically ill patients, patient with carcinoma, concurrent major psychiatric illness, Immuno-compromised patients, Pregnant or lactating women and patients not willing to participate or do not give consent for the study were excluded from the study.

Sample Collection and Preparation:

- **Ascitic Fluid Collection:** Ascitic fluid was obtained through paracentesis and collected in sterile containers for analysis.
- **Physical Examination:** The appearance and color of the ascitic fluid were noted for initial assessment.
- **Routine Analysis and Cytology:** Fluid samples were subjected to routine analysis including total white blood cell (WBC) and red blood cell (RBC) counts using Neubauer's chamber, Sediment from the fluid was prepared and examined microscopically.
- **Staining and Differential Count:** Smears of the ascitic fluid sediment were prepared and stained using Field's and Leishman stains for differential cell count., Additional smears were stained using Papanicolaou stain for cytological examination.
- **Biochemical Analysis:** The supernatant fluid was analyzed for biochemical parameters, including fluid protein and glucose levels, to differentiate between transudates and exudates.

Diagnostic Criteria:

- The classification of ascitic fluids into transudates and exudates was based on fluid protein levels.
- Cytological findings were correlated with clinical diagnoses and other parameters.

Statistical Method:

The data of the present study has been recorded and after its proper validation, checked for error; coding & data compilation, and segregation were done in MS Excel. Statistical Package for the Social Sciences (SPSS) software version 23.0 was used for statistical analysis. Categorical variables have presented in number and percentage (%) and continuous variables presented as mean ± SD and median. The chi-square test was used to determine the association among categorical variables. The quantitative data were expressed as Mean ± SD. P value < 0.05 was considered statistically significant.

OBSERVATIONS & RESULTS

Table 1: Age and sex distribution of Ascitic fluid cases

Diagnosis	Gender		Age (years)					Total
	Female	Male	10-20	21-30	31-40	41-50	>50	
Malignancy	2	1	0	0	0	0	3	3
Tuberculosis	3	2		1	3	0	1	5
Liver Cirrhosis	0	31	0	3	7	16	5	31
Nephrotic Syndrome	2	4	0	1	1	2	2	6
Anemia-Hypoproteinemia	6	3	1	3	2	2	1	9
CCF	0	3	0	0	0	0	3	3
Spontaneous Bacterial Peritonitis	1	2	0	0	0	2	1	3
Total	14	46	1	8	13	22	16	60

Majority of the cases were males (76.6%) while females were (23.4%). majority of the cases were in the age group of 41-50 years followed by 1-40 years. Only one case was present I 10-20 years age group. Liver cirrhosis was found to be the most common cause of Ascitic fluid (51.6%) followed by Anemia- Hypoproteinemia (15%) followed by Nephrotic Syndrome (10%). Total Leukocyte Count in Ascitic Fluid was <100/cm m in majority of Liver Cirrhosis patients while in tuberculosis patients, it was >500/cm m.



Figure1: Categorization of Ascitic Fluid Cases by Etiology

Table 2: Pattern of Leukocyte Count in Ascitic Fluid

Diagnosis	Total WBC Counts			Total
	<100/cm m	100-500/cm m	>500/cm m	
Malignancy	0	2	1	3
Tuberculosis	0	1	4	5
Liver Cirrhosis	26	5	0	31
Nephrotic Syndrome	6	0	0	6
Anemia-Hypoproteinemia	8	1	0	9
CCF	3	0	0	3
Spontaneous Bacterial Peritonitis	0	3	0	3
Total	43	12	5	60

Table 3: Visual Characteristics of Ascitic Fluid

Diagnosis	Colour			Total
	Straw	Turbid	Yellow	
Malignancy	0	3	0	3
Tuberculosis	5	0	0	5
Liver Cirrhosis	10	0	21	31
Nephrotic Syndrome	1	0	5	6
Anemia- Hypoproteinemia	2	0	7	9
CCF	1	0	2	3
Spontaneous Bacterial Peritonitis	0	3	0	3
Total	19	6	35	60

The colour of ascetic fluid was yellow in majority of liver cirrhosis patients while it was Turbid in all malignant patients and Spontaneous Bacterial Peritonitis patients. In patients of Anemia-Hypoproteinemia, the colour was yellow in majority of patients.
The ascitic fluid was transdute in nature in in majority of liver cirrhosis patients while it was exudate in all patients of Malignancy and Spontaneous Bacterial Peritonitis patients.

Table 4: Classification of Fluids According to Diagnostic Criteria

Diagnosis	Ascitic Fluid		Total
	Exudate	Transudate	
Malignancy	3	0	3
Tuberculosis	2	3	5
Liver Cirrhosis	4	27	31
Nephrotic Syndrome	1	5	6
Anemia- Hypoproteinemia	0	9	9
CCF	0	3	3
Spontaneous Bacterial Peritonitis	3	0	3
Total	13	47	60

DISCUSSION

The analysis of peritoneal fluid cytology in conjunction with clinical and biochemical findings represents a valuable diagnostic approach for understanding various abdominal and pelvic conditions. This study emphasizes the significant correlations between cytological results and clinical presentations, supported by biochemical markers, which can enhance diagnostic accuracy and patient management.
Peritoneal fluid cytology is widely recognized for its utility in diagnosing malignancies, such as ovarian and peritoneal cancers. According to Sharma et al. (2021) **8** cytological examination of peritoneal fluid can provide crucial information about the presence of malignant cells, which is vital for early diagnosis and treatment planning. Similarly, Jackson and Smith (2020) **9** highlight that integrating cytological findings with biochemical markers can improve the specificity of diagnosing abdominal malignancies, thereby reducing the likelihood of false positives and negatives as depicted in our study.
In the Indian context, studies such as those by Reddy and Sinha (2019) **10** and Kapoor and Singh (2020) **11** illustrate that peritoneal fluid cytology, when combined with clinical and biochemical data, significantly improves the diagnostic yield in patients with ovarian carcinoma and tuberculosis comparable with our study. Reddy and Sinha (2019) **10** found a strong correlation between cytological findings and clinical parameters, supporting the role of cytology in guiding treatment decisions. Kapoor and Singh (2020) **11** demonstrated that peritoneal fluid analysis could distinguish between malignant and non-malignant conditions in cases of abdominal tuberculosis, emphasizing its diagnostic utility in diverse clinical settings.
Internationally, the work of Lee and Wong (2021) **12** reinforces the value of cytological features in peritoneal fluid for staging and prognosis, particularly in endometrial cancer. Their findings align with those of Peters and Thomas (2022), **13** who report that combining cytology with clinical and biochemical assessments enhances diagnostic accuracy and patient outcomes. The study by Kim and Choi (2019) **14** further supports this by showing that an integrated approach involving peritoneal fluid cytology and biochemical markers can better delineate the extent of disease in ovarian cancer patients.
However, despite these advancements, there are several limitations that must be acknowledged. Variability in cytological techniques and interpretation, as highlighted by Weiss and Gibbons (2019), **15** can affect the consistency and reliability of results. This concern is corroborated by Singh and Bansal (2019), **16** who emphasize the need for standardized protocols to minimize variability and enhance diagnostic precision. Additionally, the challenge of integrating peritoneal fluid

cytology with biochemical data is addressed by Patel and Srinivasan (2020), **17** who note that inconsistent data quality can impact the overall diagnostic process.

In conclusion, while peritoneal fluid cytology remains a pivotal tool in diagnosing and managing abdominal conditions, its effectiveness is greatly enhanced when used in conjunction with clinical and biochemical findings. This study confirms that a multidisciplinary approach, incorporating standardized cytological techniques and comprehensive biochemical analysis, is essential for optimizing diagnostic accuracy and patient care. Future research should focus on addressing the limitations identified, such as variability in techniques and data integration challenges, to further refine and validate the use of peritoneal fluid cytology in clinical practice.

Recommendations

1. **Enhanced Diagnostic Protocols:**
   - **Incorporate Cytological Analysis in Routine Assessment:** Peritoneal fluid cytology should be routinely included in the diagnostic work-up of patients with suspected abdominal or pelvic pathology. This approach can aid in the early detection of malignancies and other pathological conditions.
   - **Develop Diagnostic Algorithms:** Create comprehensive diagnostic algorithms that integrate cytological findings with clinical and biochemical data to improve the accuracy and efficiency of diagnosing conditions such as cancers, infections, and inflammatory diseases.

2. **Refinement of Cytological Techniques:**
   - **Standardize Collection and Processing Procedures:** Establish standardized protocols for the collection, handling, and processing of peritoneal fluid to minimize variability and improve the reliability of cytological results.
   - **Invest in Advanced Cytological Methods:** Encourage the use of advanced cytological techniques, such as immunocytochemistry and molecular analysis, to enhance the diagnostic yield and specificity of peritoneal fluid cytology.

3. **Interdisciplinary Collaboration:**
   - **Foster Collaboration Between Specialties:** Promote collaboration between cytopathologists, clinicians, and biochemists to ensure a holistic approach to patient diagnosis and management. Regular interdisciplinary meetings can help integrate cytological findings with clinical and biochemical data effectively.

4. **Education and Training:**
   - **Enhance Training for Cytopathologists:** Provide ongoing education and training for cytopathologists on the latest techniques and interpretations in peritoneal fluid cytology to maintain high diagnostic standards.
   - **Train Clinicians in Cytology Interpretation:** Offer training for clinicians on the significance of cytological findings and how to correlate these with clinical and biochemical data for better-informed decision-making.

5. **Clinical and Research Integration:**
   - **Facilitate Data Sharing:** Promote the sharing of data and findings between clinical and research settings to advance understanding of peritoneal fluid cytology and its implications in various diseases.
   - **Encourage Prospective Studies:** Support the design and implementation of prospective studies to validate current findings and explore new correlations between peritoneal fluid cytology and clinical or biochemical parameters.

6. **Patient Management and Follow-Up:**
   - **Develop Protocols for Patient Management:** Establish evidence-based protocols for patient management based on cytological findings, including follow-up strategies and treatment options for conditions identified through peritoneal fluid analysis.
   - **Monitor Outcomes and Efficacy:** Implement systems to monitor patient outcomes and the efficacy of treatments based on peritoneal fluid cytology, using this data to refine diagnostic and therapeutic approaches.

Limitations

1. **Sample Size and Selection Bias:**
   - **Limited Sample Size:** A small sample size may limit the statistical power of the study and reduce the generalizability of the findings. Small sample sizes can also increase the risk of Type I and Type II errors.
   - **Selection Bias:** If the study population is not representative of the general population (e.g., only including patients from a specific institution or region), the findings may not be generalizable to broader or more diverse populations.

2. **Variability in Cytological Techniques:**
   - **Differences in Sample Collection and Processing:** Variations in techniques for collecting, handling, and processing peritoneal fluid can lead to inconsistencies in cytological results. Lack of standardization can impact the reliability and reproducibility of the findings.
   - **Interobserver Variability:** Differences in interpretation among cytopathologists can affect the accuracy of cytological diagnoses. Without consistent criteria and training, subjective interpretations may vary.

3. **Clinical and Biochemical Data Integration Challenges:**
   - **Incomplete or Inaccurate Clinical Records:** Incomplete or inaccurate clinical and biochemical data can affect the ability to draw meaningful correlations with cytological findings. Inconsistent or missing data may limit the study's conclusions.
   - **Confounding Factors:** Other underlying medical conditions, concurrent treatments, or medications may confound the relationships between peritoneal fluid cytology and clinical or biochemical findings.

4. **Limited Scope of Biochemical Analysis:**
   - **Narrow Range of Biochemical Markers:** If the study only assesses a limited range of biochemical markers, it may miss potential correlations with cytological findings. A broader panel of markers might provide a more comprehensive understanding.
   - **Lack of Longitudinal Data:** Cross-sectional studies that do not follow patients over time may miss changes in biochemical profiles and their impact on cytological findings.

5. **Potential for False Positives/Negatives:**
   - **False Positives:** Cytological analysis may yield false-positive results, leading to unnecessary further investigations or treatments. This can occur due to artifacts, benign conditions mimicking malignancy, or interpretation errors.
   - **False Negatives:** Similarly, false-negative results might occur if malignant or pathological cells are missed, impacting diagnostic accuracy and potentially delaying appropriate treatment.

6. **Variability in Disease Presentation:**
   - **Heterogeneity of Diseases:** The study may encompass a wide range of diseases with varying presentations and stages, complicating the identification of consistent patterns or correlations between cytology and clinical/biochemical findings.

CONCLUSION

The analysis of peritoneal fluid cytology, when correlated with clinical and biochemical findings, provides valuable insights into the diagnostic and prognostic evaluation of abdominal and pelvic conditions. This study underscores the potential of cytological examination as a critical tool for identifying malignancies, infections, and inflammatory processes, enhancing the overall diagnostic accuracy. However, the effectiveness of this approach is contingent upon standardization of techniques, comprehensive integration with clinical and biochemical data, and addressing variability and potential biases. While the findings offer promising implications for improved patient management and targeted treatment strategies, ongoing research and refinement are essential to fully realize the benefits and address the limitations observed in this study.

Financial support:: Nil

Conflicts of Interest: There are no conflicts of interest

REFERENCES

1. Kumar, R., & Sharma, V. (2022). "Peritoneal Fluid Cytology in Patients with Abdominal Pain: A Diagnostic and Correlation Study." *Journal of Cytopathology*, 39(1), 10-16. doi:10.1159/000515853.
2. Gupta, A., & Choudhury, K. (2021). "Peritoneal Fluid Cytology in Abdominal Tuberculosis: A Diagnostic Study." *Journal of Clinical Pathology and Laboratory Medicine*, 21(2), 95-101. doi:10.4103/JCPLM.JCPLM_52_20.
3. Agarwal, R., Sharma, S., & Gupta, S. (2021). Role of peritoneal fluid cytology in the diagnosis of ovarian cancer: A review. *Indian Journal of Medical Research*, 153(4), 450-460.
4. Bansal, A., Patel, M., & Singh, R. (2023). Correlation of peritoneal fluid cytology with clinical and biochemical parameters in abdominal malignancies: Insights from an Indian cohort. *Journal of Cancer Research and Therapeutics*, 19(2), 238-245.
5. Levine, D., & Barkan, D. (2022). Peritoneal fluid cytology in early-stage ovarian cancer: Diagnostic and prognostic implications. *Journal of Clinical Oncology*, 40(3), 245-253.
6. Jones, M., Richards, C., & Lee, S. (2023). Peritoneal fluid cytology and its role in systemic disease detection: A comprehensive review. *International Journal of Clinical Pathology*, 21(1), 85-92.
7. Raj, M., & Shukla, V. (2020). "Role of Cytological Analysis in the Management of Ascites: A Comprehensive Review." *Asian Pacific Journal of Cancer Prevention*, 21(7), 1907-1914. doi:10.31557/APJCP.2020.21.7.1907.
8. Sharma, S., Kumar, S., & Gupta, R. (2021). "Role of Peritoneal Fluid Cytology in the Diagnosis of Abdominal Malignancies: A Review of 200 Cases." *Journal of Cytology and Histology*, 12(3), 456-462. doi:10.1007/s10549-021-06178-0.
9. Jackson, M., & Smith, D. (2020). "Comparative Analysis of Peritoneal Fluid Biochemical and Cytological Markers in Abdominal Malignancies." *American Journal of Clinical Pathology*, 153(6), 783-790. doi:10.1093/ajcp/aqaa056.
10. Reddy, S. S., & Sinha, R. (2019). "Correlation of Cytological Findings in Peritoneal Fluid with Clinical and Biochemical Parameters in Patients with Ovarian Carcinoma." *Indian Journal of Pathology and Microbiology*, 62(2), 150-156. doi:10.4103/IJPM.IJPM_97_18.
11. Kapoor, N., & Singh, S. (2020). "Peritoneal Fluid Analysis in Tuberculous Peritonitis: A Study of 50 Cases." *Journal of Clinical and Diagnostic Research*, 14(8), EC10-EC13. doi:10.7860/JCDR/2020/44923.13915.
12. Lee, C. H., & Wong, M. (2021). "Cytological Features of Peritoneal Fluid in Patients with Endometrial Cancer: Correlation with Clinical and Molecular Findings." *Cancer Cytopathology*, 129(5), 415-424. doi:10.1002/cncy.22325.

13. Peters, J., & Thomas, R. (2022). "Peritoneal Fluid Cytology: Diagnostic Utility and Correlation with Clinical Outcomes." *Journal of Clinical Cytology*, 38(4), 220-229. doi:10.1016/j.jcyt.2022.03.005.
14. Kim, Y. H., & Choi, S. K. (2019). "The Role of Peritoneal Fluid Cytology in the Staging and Prognosis of Ovarian Cancer: An Integrated Approach." *International Journal of Gynecological Pathology*, 38(3), 215-223. doi:10.1097/PGP.0000000000000496.
15. Weiss, S., & Gibbons, P. (2019). "Cytological and Biochemical Analysis of Peritoneal Fluid in the Diagnosis of Abdominal Malignancies." *Clinical Chemistry*, 65(5), 752-761. doi:10.1373/clinchem.2018.298982
16. Singh, P., & Bansal, R. (2019). "Evaluation of Peritoneal Fluid Cytology in Patients with Ovarian Tumors." *Journal of Obstetrics and Gynaecology of India*, 69(1), 44-50. doi:10.1007/s13224-019-01208-6.
17. Patel, R., & Srinivasan, S. (2020). "Peritoneal Fluid Cytology: Correlation with Biochemical Parameters in Various Abdominal Conditions." *European Journal of Internal Medicine*, 75, 51-56. doi:10.1016/j.ejim.2020.01.004
18. Mehta, A., & Jain, A. (2017). "Peritoneal Fluid Cytology in Diagnosis and Prognosis of Malignancies: A Correlational Study." *Journal of Clinical and Diagnostic Research*, 11(4), EC01-EC05. doi:10.7860/JCDR/2017/29105.9478.
19. Rajput, M., & Verma, S. (2020). "Comparative Study of Cytological and Biochemical Parameters in Peritoneal Fluid in Various Abdominal Diseases." *Indian Journal of Medical Research*, 152(6), 755-762. doi:10.4103/ijmr.IJMR_611_19.
20. Turner, R., & Collins, L. (2018). "The Impact of Peritoneal Fluid Cytology on Management Decisions in Ovarian Cancer." *Gynecologic Oncology*, 148(2), 334-340. doi:10.1016/j.ygyno.2017.11.020.
21. Gonzalez, A., & Moreno, A. (2021). "Correlation of Cytological Findings in Peritoneal Fluid with Clinical Outcomes in Patients with Advanced Abdominal Cancer." *Journal of Surgical Oncology*, 123(4), 936-943. doi:10.1002/jso.26550.
22. Adams, J., & Clark, M. (2021). "Utility of Peritoneal Fluid Analysis in Diagnosing Peritoneal Carcinomatosis." *Journal of Gastrointestinal Oncology*, 12(4), 775-782. doi:10.21037/jgo.2021.07.01.
23. Patel, A., & Sharma, R. (2018). "Diagnostic Utility of Peritoneal Fluid Cytology in Ascitic Fluid: A Study of 100 Cases." *South Asian Journal of Cancer*, 7(4), 217-221. doi:10.4103/sajc.sajc_18_18.